Actinium Pharmaceuticals, Inc.
ATNM· NYSE
ATNMActinium Pharmaceuticals, Inc.
Filed Aug 9, 2018 · 10-Q · 40 days after period end · 0001213900-18-010603
| Metric | Q2 2018 | Q2 2017 | Q2 2016 | Q2 2015 |
|---|---|---|---|---|
| Net Income | -$4.86M | -$7.05M | -$6.62M | -$7.46M |
| EPS Diluted | -$0.04 | -$0.12 | -$0.15 | -$0.20 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Jun 30, 2018 · filed Aug 9, 2018 · 40 d after period end
